<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The combination of <z:chebi fb="0" ids="26995">thromboxane</z:chebi> (TX) synthase inhibition and <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> (PG) H2/<z:chebi fb="0" ids="15627">TXA2</z:chebi> receptor antagonism yields enhanced antithrombotic effects as compared with either intervention alone </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is not known whether the enhancing effect of TX synthase inhibition is expressed also in the presence of complete blockade of <z:chebi fb="0" ids="15554">PGH2</z:chebi>/<z:chebi fb="0" ids="15627">TXA2</z:chebi> receptors </plain></SENT>
<SENT sid="2" pm="."><plain>Thus we evaluated the antithrombotic effects of increasing doses of the <z:chebi fb="0" ids="15554">PGH2</z:chebi>/<z:chebi fb="0" ids="15627">TXA2</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> L 670596 alone and in combination with a dose of the TX synthase inhibitor FCE 22178 causing &gt; 95% inhibition of platelet <z:chebi fb="0" ids="28728">TXB2</z:chebi> production </plain></SENT>
<SENT sid="3" pm="."><plain>In the dog model of electrically induced coronary <z:mp ids='MP_0005048'>thrombosis</z:mp>, occlusion time in control animals (n = 14) averaged 72 +/- 29 min </plain></SENT>
<SENT sid="4" pm="."><plain>L 670596 alone dose-dependently antagonized platelet <z:chebi fb="0" ids="15554">PGH2</z:chebi>/<z:chebi fb="0" ids="15627">TXA2</z:chebi> receptors and prolonged occlusion time </plain></SENT>
<SENT sid="5" pm="."><plain>The addition of FCE 22178 displaced the dose-occlusion time relation of L 670596 in a parallel fashion without modifying receptor occupancy </plain></SENT>
<SENT sid="6" pm="."><plain>In the rabbit model of copper coil-induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp>, occlusion was very rapid (14 +/- 4 min) in control animals (n = 17) and was not modified by either aspirin or FCE 22178 </plain></SENT>
<SENT sid="7" pm="."><plain>L 670596 caused a dose-related receptor blockade and prolongation of occlusion time </plain></SENT>
<SENT sid="8" pm="."><plain>The association with FCE 22178 enhanced significantly the antithrombotic effect of L 670596 at <z:hpo ids='HP_0000001'>all</z:hpo> doses </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that the full therapeutic potential of <z:chebi fb="0" ids="15554">PGH2</z:chebi>/<z:chebi fb="0" ids="15627">TXA2</z:chebi> receptor antagonism is expressed at &gt; 90% platelet receptor occupancy </plain></SENT>
<SENT sid="10" pm="."><plain>The additive effect of TX synthase inhibition suggests that conversion of <z:chebi fb="0" ids="15554">PGH2</z:chebi> to platelet-inhibitor and <z:chebi fb="1" ids="35620">vasodilator</z:chebi> <z:chebi fb="11" ids="26333">prostaglandins</z:chebi> might be of therapeutic importance, irrespective of the extent of <z:chebi fb="0" ids="15554">PGH2</z:chebi>/<z:chebi fb="0" ids="15627">TXA2</z:chebi> receptor blockade </plain></SENT>
</text></document>